Stocks Health care RNXT
NASDAQ · Health careRenovoRx, Inc. (RNXT)
RenovoRx, Inc. brought in $2M of revenue over the twelve months to June 30, 2026. It posted a net loss of $12.3M. In fiscal 2025 capital spending exceeded operating cash flow by $11M. At June 30, 2026 it held $9.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about RenovoRx, Inc.
- Net worth
- RenovoRx, Inc. has a market value (market cap) of $53.3M at the latest share price, and shareholders' equity of $9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.1M (+2,511.6% year on year), with a net loss of $11.2M. Over the 12 months to June 30, 2026: revenue $2M, net loss $12.3M.
- Cash flow
- In fiscal 2025 operations used $11M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- RenovoRx, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What RenovoRx, Inc. does
RenovoRx, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker RNXT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.1M | -$11.2M | -$0.32 | -$11M |
| 2024 | $43K | -$8.8M | -$0.40 | -$9.1M |
| 2023 | n/a | -$10.2M | -$0.99 | n/a |
| 2022 | n/a | -$9.9M | -$1.09 | n/a |
| 2021 | n/a | -$6.3M | -$1.21 | n/a |
| 2021 | n/a | -$3.8M | -$1.72 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RNXT ranks in Health care
Latest SEC filings
What RenovoRx, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 20, 2026Other event 8-K
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 115% to $909K versus the same quarter last year; diluted EPS -$0.06 versus -$0.08.
- August 13, 2026Quarterly results 8-K/A
- August 12, 2026Exhibits 8-K
- August 4, 2026Other event 8-K
- July 2, 2026
- June 30, 2026
- June 30, 2026
- May 15, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 2,512% to $1.1M versus the prior year; diluted EPS -$0.32 versus -$0.40.
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 186% to $563K versus the same quarter last year; diluted EPS -$0.09 versus -$0.08.
Insider trades
What the people running RenovoRx, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Voll MarkChief Financial Officer | Received as pay | 80,000 | - |
| May 19, 2026 | Voll MarkChief Financial Officer | Bought | 25,000 | $19.7K |
| April 3, 2026 | Voll MarkChief Financial Officer | Received as pay | 80,000 | - |
| March 25, 2026 | Voll MarkChief Financial Officer | Received as pay | 12,380 | - |
| March 20, 2026 | Voll MarkChief Financial Officer | Boughtindirect | 97,200 | - |
| March 20, 2026 | Bagai ShaunChief Executive Officer, Director | Boughtindirect | 24,300 | - |
| March 20, 2026 | Marton LaurenceDirector | Boughtindirect | 9,720 | - |
| January 21, 2026 | Agah RamtinChief Medical Officer, Director | Bought | 10,000 | $10K |
Who owns RNXT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| AIGH Capital Management LLC13G, passive with 1 related filers | 9.8% | April 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 28 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| AIGH Capital Management LLC | 4,405,439 | +699,242 |
| Bleichroeder LP | 1,666,098 | 0 |
| Vanguard Capital Management LLC | 1,443,742 | -3,435 |
| Geode Capital Management, LLC | 424,148 | +42,425 |
| Wealthspire Advisors, LLC | 252,525 | 0 |
| Vanguard Fiduciary Trust Co | 240,330 | +82,428 |
| Citadel Advisors LLC | 133,597 | -99,087 |
| Northern Trust Corp | 85,207 | +43,046 |
| Chicago Partners Investment Group LLC | 92,356 | 0 |
| Northwestern Mutual Wealth Management Co | 74,596 | -24,864 |
| Caprock Group, LLC | 63,940 | 0 |
| Jane Street Group, LLC | 46,399 | +22,262 |
| Kestra Advisory Services, LLC | 35,520 | 0 |
| Two Sigma Securities, LLC | 34,788 | +16,892 |
| XTX Topco Ltd | 29,983 | -528 |
| Clear Creek Financial Management, LLC | 29,058 | new |
| State Street Corp | 26,152 | 0 |
| UBS Group AG | 20,820 | +17,482 |
| HighTower Advisors, LLC | 20,000 | 0 |
| Cetera Investment Advisers | 19,000 | +1,000 |
Insiders
5 insiders reported holding 1,878,322 shares in total, about $2.2M at the last price.
| Holder | Shares |
|---|---|
| Agah RamtinChief Medical Officer, Director | 798,460 |
| Bagai ShaunChief Executive Officer, Director | 653,397313,357 held indirectly |
| Voll MarkChief Financial Officer | 319,58097,200 held indirectly |
| Ryan Una SDirector | 97,16597,165 held indirectly |
| Marton LaurenceDirector | 9,7209,720 held indirectly |
Questions about RNXT
What does RenovoRx, Inc. do?
RenovoRx, Inc. is a company in the Health care sector, listed on NASDAQ as RNXT. Its shares trade on NASDAQ under the ticker RNXT.
What is RenovoRx, Inc.'s net worth?
RenovoRx, Inc. has a market value (market cap) of $53.3M at the latest share price, and shareholders' equity of $9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is RenovoRx, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.3M on revenue of $2M.
How much revenue does RenovoRx, Inc. make?
Over the twelve months to June 30, 2026 RenovoRx, Inc. reported revenue of $2M.
When did RenovoRx, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is RenovoRx, Inc.'s next earnings report?
RenovoRx, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RNXT with
Follow RNXT
Get an email when RenovoRx, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values RenovoRx, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.